Fluconozole Powder

Fluconozole Powder

Form: Powder for Oral Suspension

Strength: 350 mg, 1400mg(to be reconstituted)

Reference Brands: Diflucan(EU & US) and Generics

Category: Anti-fungal

Fluconazole powder for suspension is approved in the EU and US for pediatric and oral use. In the EU, Pfizer’s Diflucan powder is regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, the FDA has approved Diflucan powder based on comprehensive clinical data and biosimilarity assessments, with ongoing pharmacovigilance. Both regions require detailed dossiers for approval, ensuring product quality and safety. For expert assistance with pharmaceutical dossiers, regulatory filings, and compliance, visit Pharmatradz, your trusted partner in regulatory solutions, helping expedite market access and ensuring adherence to regulatory standards.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Nystatin Oral Suspensions/Tablets

Strength: Tab: 500,000 units, 1,000,000 units; Sus: 100,000 units/mL, 500,000 units/5 mL

Form: Tablets/Suspensions

Reference Brands: Mycostatin, Nilstat, Nystop(US)

View Details Get Enquiry
Nystatin Topical Creams and Ointments

Strength: 100,000 units/g, 100,000–300,000 units/g

Form: Topical Creams and Ointments

Reference Brands: Mycostatin, Nilstat, Nystop(US)

View Details Get Enquiry
Micafungin Intravenous (IV) Powder

Strength: 50 mg, 100 mg/vial

Form: Intravenous (IV) Powder

Reference Brands: Mycamine(US & EU)

View Details Get Enquiry
Anidulafungin injection

Strength: 50 mg/vial

Form: Intravenous (IV) Powder

Reference Brands: Eraxis(US)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.